Rising legal and regulatory scrutiny of compounded weight loss drugs suggests branded pharma ties are the safer avenue for telehealth players to sell their copycat GLP-1s.

Midi Health’s growth shows sustained focus on women’s care can fuel digital health trust and scale.

The biggest women’s health opportunity may actually be in common diseases that affect women differently and go ignored.

From TikTok to pharma sites, women’s go-to channels shift by life stage—and marketers need to follow.

Women use more healthcare, spend more on prescriptions, and are spurring telehealth companies to deliver tailored virtual services.

More than half of women received a mental health diagnosis after perimenopause symptoms began, according to a Biote survey in August. For healthcare providers, adding basic perimenopause assessments to routine visits can help distinguish hormonal shifts from mental health conditions.

WeightWatchers launched a new menopause program with Queen Latifah as its spokesperson. This move is part of a larger strategy to expand into the clinical healthcare and prescription medication markets. To succeed against rivals like Hims & Hers and Noom, WeightWatchers needs to offer competitive pricing and secure more partnerships with major pharmaceutical companies to help raise awareness of its new focus in the growing wellness sector.

The news: An FDA panel endorsed the removal of black box warnings on hormone therapies used for menopause. For context: Black box warnings are the strongest safety warning issued by the FDA for Rx drugs and highlight serious or life-threatening risks. Our take: Removing the black box warning could encourage pharma brands to not only develop more treatments but also market hormone therapy more. While personal risks and benefits still need to be weighed with a doctor, the change may result in more women on treatment.

The news: Dr. Kim Boyd, previously the chief medical officer of telehealth weight loss startup Calibrate, joins WeightWatchers as CMO as the company plans to launch perimenopause, menopause and post-menopause treatments and services for women ages 40-60 later this year. Our take: WeightWatchers will compete with several D2C telehealth for the underserved pre- and post-menopausal consumer market. However, we think its brand recognition among women ages 40-60, its long-standing weight loss support expertise and new Novo deal could catapult it ahead.

Noom expands into hormone replacement therapy: Companies must tread carefully as they enter a new prescription drug segment that comes with medical risks.

Investments in women’s health startups are alarmingly low: Yet startups addressing conditions such as menopause have seen success when VC funding has gone their way, showing that investments in the space have a high potential for viable returns.